title: RNA targeted therapeutics for hematologic malignancies.
abstract: In a variety of experimental systems, antisense nucleic acids (ASNA) of various composition, including antisense oligodeoxynucleotides (ODN) and siRNA, have been shown to have the ability to variably perturb gene expression in a sequence specific manner. Pilot clinical studies from our group, and others, have demonstrated that gene silencing is a therapeutic strategy that is starting to make a real contribution to the treatment of various diseases. The development of this field, with specific reference to hematologic malignancies, is reviewed very briefly below.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine and Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. gewirtz@mail.med.upenn.edu
authors.forename: Alan M
authors.initials: AM
authors.lastname: Gewirtz
mesh_terms: D020868:Gene Silencing; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D020319:Oligodeoxyribonucleotides, Antisense / Q000627:therapeutic use; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D034741:RNA, Small Interfering / Q000627:therapeutic use
chemical_list: D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering